Tag: Paragon BioTeck
Ruling Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formula
PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc. (Paragon), announces a monumental ruling handed down by the United States Patent and Trademark Office affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
Paragon BioTeck Announces Call for 2017 Koch Kellan Medical Scholarship Applicants
PORTLAND, Ore., Sept. 1, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today a call for applications for the 2017 Koch Kellan Scholarship, awarded annually to an outstanding graduate medical student committed to pursuing a clinical, teaching or research career in ophthalmology. A Paragon Gives initiative, the Koch Kellan Scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs and improve the quality of lives around the world.
Paragon BioTeck to Attend 34th Annual J.P. Morgan Healthcare Conference
PORTLAND, Ore., -- Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, January 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.
